Professor Janet Shipley’s team is investigating ways to improve the treatment of patients with soft tissue sarcomas associated with poor clinical outcome.
Professor Janet Shipley is investigating ways to improve the treatment of patients with sarcomas that have a poor outcome.
I joined the ICR in 2013. I work on the development and characterisation of 3D and PDX models of paediatric sarcomas. I use these models to study new therapies that combine standard chemotherapy with targeting drugs.
I am a Clinical Research Fellow interested in understanding the complexities of cancer and bridging the gap between researchers and clinicians. My current project is focused on understanding whether tumour hypoxia can be targeted, and used as a predictive biomarker to improve treatment response, in patients with aggressive forms of rhabdomyosarcoma.
My research interests lie within translational cancer research to develop better therapeutic interventions for patients. Currently, I am working on combination treatments for the targeted therapy of rare paediatric sarcomas.
I am currently developing three dimensional spheroid models for paediatric soft tissue sarcomas. The in vitro models will serve as invaluable tools for testing novel treatment strategies as well as for understanding the role of the tumour stroma on these rare and often aggressive tumours.
I’m in the final year of my PhD in Ewing Sarcoma. My research aim is to identify novel therapeutic strategies for this rare cancer through combination strategies using spheroid models and molecular biology techniques.
I work on rhabdomyosarcoma, an aggressive cancer of the soft tissue which is most common in children and young adults. My project is focused on developing a new circulating tumour DNA-based blood test which will hopefully enable earlier detection of treatment failure and disease recurrence in paediatric rhabdomyosarcoma patients.
I am a Senior Scientific Officer and am involved in several projects looking at rhabdomyosarcoma. These involve trying to improve the prognostication of rhabdomyosarcoma as well as identifying new drug targets and approaches to treating rhabdomyosarcoma to achieve better outcomes while sparing children unnecessary treatment and therefore side effects that can affect them in later life.
I joined the team in 1992 working mainly with rhabdomyosarcoma and testicular germ cell tumours. Since 2014 I have worked on a voluntary basis cataloguing the department's tissue assets.